Navigation Links
CareFusion and ResMed Announce Distribution Agreement for U.S. Hospital Market
Date:7/25/2011

SAN DIEGO, July 25, 2011 /PRNewswire/ -- CareFusion (NYSE: CFN), a leading, global medical technology company and ResMed (NYSE: RMD), a leading developer, manufacturer and distributor of medical equipment for treating, diagnosing and managing sleep-disordered breathing and other respiratory disorders today announced a five-year agreement providing CareFusion the exclusive right to distribute the ResMed Stellar™ 100 and 150 non-invasive ventilators (NIV) and their related accessories into the U.S. institutional healthcare market.

The agreement, effective immediately, provides strategic benefits to both companies. CareFusion will now have a more competitive offering in the institutional NIV market, which is expected to grow by more than 6 percent annually. For ResMed, it provides a timely introduction of its new ventilation products, with their unique performance, size and mobility features valuable to clinicians, caregivers and patients, via CareFusion's long-standing relationships with U.S. hospitals, long-term acute care and skilled nursing facilities. CareFusion will also market and sell the Stellar 100 and 150 related accessories, including tubing and filters.

"The addition of ResMed's Stellar ventilator fills an important need in the respiratory care market segment for our customers," said Tony Lopez, senior vice president and general manager of Respiratory Care at CareFusion. "This strategic agreement also directly aligns with our mission to improve health care costs and quality care to patients."

"Our partnership with CareFusion creates a strong strategic fit and allows ResMed to effectively address the U.S. institutional market with an established leader in the industry," commented Geoff Neilson, ResMed's president, respiratory care strategic business unit. "The Stellar ventilator provides CareFusion with a product having differentiated features and a competitive price point. We have established a good relationship with CareFusion and look forward to it being a long-standing one."  

About the Stellar 100 and 150 non-invasive ventilators

The Stellar ventilators are small, quiet, and versatile and deliver ResMed's high-quality ventilation performance for adult and pediatric patients, with both invasive and non-invasive applications. In addition, it has several monitoring features caregivers will especially appreciate, such as ResMed's leading leak-compensation algorithm, TiControl™ and on-screen waveforms for managing leak and patient-ventilator synchrony — two common problems that occur when administering non-invasive ventilation in an institutional setting. It is also portable with a built-in rechargeable battery. The ResMed Stellar 100 and 150 were cleared by the Food and Drug Administration (FDA) earlier this year.

About ResMed

ResMed is a leading developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing.

Further information can be obtained by visiting the Company's multilingual Web site at www.resmed.com.

About CareFusion

CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve patient care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AirLife™, AVEA® and LTV® series of ventilators and respiratory products, ChloraPrep® skin prep products, MedMined™ services for data mining surveillance, V. Mueller® and Snowden-Pencer® surgical instruments and NeuroCare diagnostic products. CareFusion employs more than 14,000 people across its global operations. More information may be found at www.carefusion.com.

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding ResMed's and CareFusion's future revenue, earnings or expenses, new product development and new markets for both companies' products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the companies' Annual Report on Form 10-K for its most recent fiscal year and in other reports the companies file with the U.S. Securities & Exchange Commission. Those reports are available on the companies' Web sites.


'/>"/>
SOURCE CareFusion; ResMed
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition
2. CareFusion Earns Top Ranking in MD Buyline and KLAS Reports
3. CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010
4. CareFusion Shipping Ventilators to CDC for National Emergency Preparedness
5. CareFusion Moves First Quarter Earnings Announcement to November 5
6. CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health
7. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
8. CareFusion Signs Exclusive Partnership Agreement With Minimally Invasive Devices to Distribute FloShield Laparoscopic Technology
9. CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM)
10. CareFusion Will Host an Earnings Conference Call on Feb. 9 to Discuss the Results for the Second Quarter of Fiscal 2010
11. FDA Lifts Injunction on Manufacture and Sale of CareFusion Alaris(R) SE Pump
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)...  Hologic, Inc. (Nasdaq: HOLX ) ... fiscal second quarter ended March 26, 2016.  GAAP ... 41.2%, and non-GAAP diluted EPS of $0.47 increased ... a reported basis, and 6.3% on a constant ... good quarter, highlighted by 14.6% growth in non-GAAP ...
(Date:4/27/2016)... , le 27 Avril 2016 ... d,affaires a progressé de +5% sur le trimestre, ... récurrentes de consommables  Croissance de +16% ... Mauna Kea Technologies (Euronext : MKEA, ... d,endomicroscopie confocale laser, annonce aujourd,hui son chiffre d,affaires ...
(Date:4/27/2016)... -- Elekta today announced that its leading-edge ... focal point of seven scientific presentations at ESTRO 35, ... & Oncology, taking place April 29 - May 3. ... and a high-field MRI scanner with sophisticated software that ... in real time. The MR-linac is designed to improve ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... Since launching its annual volunteer campaign on ... footwear industry, has broken all previous participation records in its first two weeks ... during the months of April and May, the 2016 Footwear Cares initiative is ...
(Date:4/29/2016)... , ... April 29, 2016 , ... On Tuesday, April ... across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the ... Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations which ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s ... Sunday, with sunny skies, a light breeze and temperatures in the 60s. Over 400 ... 5k Run and Walk and 1-mile walk were held to increase awareness about ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... student team BioCellection won the $30,000 Perlman Grand Prize of the 2016 Wharton ... Undergraduate Award, the Michelson People’s Choice Award, and the Committee Award for Most ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. ... for the majority of skin cancer deaths. More than 10,000 people are expected to die ... diagnosis is 62, it is the one of the most commonly diagnosed cancers in young ...
Breaking Medicine News(10 mins):